Vapotherm (NYSE:VAPO) had its price target decreased by equities researchers at Canaccord Genuity Group from $41.00 to $35.00 in a report released on Thursday, The Fly reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 103.61% from the stock’s current price.
Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Vapotherm from a “buy” rating to a “hold” rating in a research report on Tuesday, October 26th. BTIG Research reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Vapotherm in a research report on Monday, September 27th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $34.80.
VAPO opened at $17.19 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.46 and a quick ratio of 2.76. The company’s 50-day moving average is $21.20 and its 200 day moving average is $23.23. Vapotherm has a fifty-two week low of $16.64 and a fifty-two week high of $38.46. The firm has a market capitalization of $448.19 million, a P/E ratio of -7.61 and a beta of -1.33.
In other news, SVP Gregoire Ramade sold 2,000 shares of Vapotherm stock in a transaction dated Thursday, November 4th. The shares were sold at an average price of $25.03, for a total value of $50,060.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.80% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in Vapotherm by 2.3% during the third quarter. BlackRock Inc. now owns 1,688,222 shares of the company’s stock valued at $37,597,000 after acquiring an additional 37,799 shares in the last quarter. Champlain Investment Partners LLC grew its stake in Vapotherm by 60.0% during the second quarter. Champlain Investment Partners LLC now owns 1,517,170 shares of the company’s stock valued at $35,866,000 after acquiring an additional 569,205 shares in the last quarter. Vanguard Group Inc. grew its stake in Vapotherm by 2.6% during the second quarter. Vanguard Group Inc. now owns 1,038,813 shares of the company’s stock valued at $24,558,000 after acquiring an additional 26,220 shares in the last quarter. State Street Corp grew its stake in Vapotherm by 17.1% during the second quarter. State Street Corp now owns 821,700 shares of the company’s stock valued at $19,425,000 after acquiring an additional 120,159 shares in the last quarter. Finally, RiverVest Venture Management LLC grew its stake in Vapotherm by 1.6% during the second quarter. RiverVest Venture Management LLC now owns 614,623 shares of the company’s stock valued at $14,530,000 after acquiring an additional 9,649 shares in the last quarter. 70.41% of the stock is owned by institutional investors.
Vapotherm Company Profile
Vapotherm, Inc is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. Its products include Precision Flow, Precision Flow Heliox, Oxygen Assist Module, Nitric Oxidie Disposable Patient Circuit, Tracheostomy Adapter, and Aerogen Adapter.
See Also: What is a Roth IRA?
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.